December 17, 2020
A combination therapy of Eisai’s multi-kinase inhibitor Lenvima (lenvatinib) plus US Merck’s PD-1 inhibitor Keytruda (pembrolizumab) demonstrated survival benefits in a global PIII study for previously treated advanced endometrial cancer, the two partners said on December 16. The trial, dubbed...read more